Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Gunda, Daniel W ^a   Kasang, Christa ^b,c   Kidenya, Benson R ^a   Kabangila, Rodrick ^a   Mshana, Stephen E ^a   Kidola, Jeremiah ^d   Kalluvya, Samuel E ^a   Kongola, Gilbert W ^a   Klinker, Hartwig ^b  

^a CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Medical Mission Institute   (Germany)

^d NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS NEVIRAPINE PLUS TENOFOVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; TANZANIA; TERTIARY HEALTH CARE; VIRUS LOAD;

ADULT; BENZOXAZINES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TANZANIA; VIRAL LOAD;

EID: 84883751630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075118     Document Type: Article

References (39)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13): 853-60.
2. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, et al. (1998) Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12(13): 1619-24.
3. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, et al. (2004) Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 23(4): 471-8.
4. Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, et al. (2004) GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 5(5): 352-9.
5. Kredo T, Van der Walt JS, Siegfried N, Cohen K, (2009) Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev (3): CD007268.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, et al. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1): 71-5.
7. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, et al. (2001) High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 15(9): 1089-95.
8. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM, (1999) Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13(4): 473-8.
9. Clevenbergh P, Mouly S, Sellier P, Badsi E, Cervoni J, et al. (2004) Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view. Curr HIV Res 2(4): 309-21.
10. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, et al. (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 179(5): 1116-23.
11. Kiser JJ, Anderson PL, Gerber JG, (2005) Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs. Curr HIV/AIDS Rep 2(2): 61-7.
12. Duong M, Golzi A, Peytavin G, Piroth L, Froidure M, et al. (2004) Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice. HIV Clin Trials 5(4): 216-23.
13. Gazzard BG, (1999) Efavirenz in the management of HIV infection. Int J Clin Pract 53(1): 60-4.
14. Rendon A, Nunez M, Jimenez-Nacher I, Gonzalez de Requena D, Gonzalez-Lahoz J, et al. (2005) Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 6(5): 360-5.
15. Acosta EP, Gerber JG, (2002) Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 18(12): 825-34.
16. Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, et al. (2005) Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 10(4): 489-98.
17. Kontorinis N, Dieterich DT, (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23(2): 173-82.
18. Dahri K, Ensom MH, (2007) Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet 46(2): 109-32.
19. van Leth F, Lange JM, (2006) The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection. Ned Tijdschr Geneeskd. 150(31): 1719-22.
20. Molto J, Clotet B, (2004) Therapeutic drug monitoring of antiretroviral agents scenario. J HIV Ther 9(4): 75-8.
21. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, et al. (2003) Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit. 25(3): 367-73.
22. Khoo SH, Lloyd J, Dalton M, Bonington A, Hart E, et al. (2006) Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 41(4): 461-7.
23. Leth FV, Kappelhoff BS, Johnson D, Losso MH, Boron-Kaczmarska A, et al. (2006) Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 22(3): 232-9.
24. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, et al. (2002) Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS Suppl 1:S5-37.
25. Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, et al. (2007) A randomized controlled trial of therapeutic drug monitoring in treatment-naive and-experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 46(4): 433-42.
26. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, et al. (2005) Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 10: 469-477.
27. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, et al. (2009) Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 23(6): 697-700.
28. Grossberg R, Gross R, (2007) Use of pharmacy refill data as a measure of antiretroviral adherence. Current HIV/AIDS Reports 4: 187-191.
29. Langmann P, Schirmer D, Väth T, Zilly M, Klinker H, (2001) High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. J Chromatogr B Biomed Sci Appl 5 755(1-2): 151-6.
30. Langmann P, Schirmer D, Väth T, Desch S, Zilly M, et al. (2002) Rapid determination of nevirapine in human plasma by gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 5 767(1): 69-74.
31. corp GhB-s (2010) COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0. Doc Rev. 5.0 ed. editor. USA: Roche molecular systems.
32. Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, et al. (2009) Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 64(1): 109-17.
33. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, et al. (2009) Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 9: 81.
34. Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, et al. (2011) Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection 39(6): 563-9.
35. Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, et al. (2003) Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 188(4): 541-8.
36. Young B, (2005) Review: mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS 19(5): 286-97.
37. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, et al. (2008) Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 6 300(5): 530-9.
38. Robertson SM, Penzak SR, Pau A, (2007) Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother 8(17): 2947-63.
39. Kasang C, Kalluvya S, Majinge C, Stich A, Bodem J, et al. (2011) HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. PLoS ONE 6(8): e23091 doi:10.1371/journal.pone.0023091).